湖岸生物上涨2.86%，报0.72美元/股，总市值2967.31万美元

Core Viewpoint - Lakeshore Biotech (LSB) shows a positive market performance with a stock price increase of 2.86% and a market capitalization of approximately $29.67 million, indicating investor confidence in the company's growth potential [1]. Financial Performance - As of March 31, 2025, Lakeshore Biotech reported total revenue of 615 million RMB, reflecting a year-on-year growth of 7.24% [1]. - The company experienced a significant increase in net profit attributable to shareholders, reporting a loss of 99.98 million RMB, which represents a year-on-year improvement of 76.93% [1]. Company Overview - Lakeshore Biotech is a Cayman Islands-registered holding company primarily operated by its domestic subsidiary, Beijing Yisheng Biotech Co., Ltd. [1]. - Beijing Yisheng Biotech is a global biopharmaceutical company focused on the discovery, development, production, and commercialization of next-generation vaccines and therapeutic biologics for infectious diseases and cancer [1].